Literature DB >> 21836610

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.

K Mihara, J Bhattacharyya, A Kitanaka, K Yanagihara, T Kubo, Y Takei, H Asaoku, Y Takihara, A Kimura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21836610     DOI： 10.1038/leu.2011.205

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  26 in total

Review 1.  Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.

Authors:  N Lendvai; A D Cohen; H J Cho
Journal:  Bone Marrow Transplant       Date:  2015-03-09       Impact factor: 5.483

Review 2.  CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

Authors:  Hollie J Pegram; Eric L Smith; Sarwish Rafiq; Renier J Brentjens
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 3.  Novel Immunotherapies for Multiple Myeloma.

Authors:  Mattia D'Agostino; Mario Boccadoro; Eric L Smith
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

4.  Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Authors:  Jianhong Chu; Shun He; Youcai Deng; Jianying Zhang; Yong Peng; Tiffany Hughes; Ling Yi; Chang-Hyuk Kwon; Qi-En Wang; Steven M Devine; Xiaoming He; Xue-Feng Bai; Craig C Hofmeister; Jianhua Yu
Journal:  Clin Cancer Res       Date:  2014-03-27       Impact factor: 12.531

Review 5.  CAR T-cell therapy: is it prime time in myeloma?

Authors:  Surbhi Sidana; Nina Shah
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Authors:  Esther Drent; Richard W J Groen; Willy A Noort; Maria Themeli; Jeroen J Lammerts van Bueren; Paul W H I Parren; Jürgen Kuball; Zsolt Sebestyen; Huipin Yuan; Joost de Bruijn; Niels W C J van de Donk; Anton C M Martens; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

Review 7.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

Review 8.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

Review 9.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

10.  CAR T-cell therapy: is it prime time in myeloma?

Authors:  Surbhi Sidana; Nina Shah
Journal:  Blood Adv       Date:  2019-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.